PBM Transparency Is Still Too Opaque — How Can Employers Rein In Drug Costs?
Employers are trying to comparison shop in a market where all the price tags are hidden. And most can’t simply switch PBMs to find better pricing for their members.
Employers are trying to comparison shop in a market where all the price tags are hidden. And most can’t simply switch PBMs to find better pricing for their members.
When the healthcare system defaults to uncertainty, people delay care because it feels safer for their wallets. In some cases, people wait too long, leaving an ER visit as the path of least resistance.
Scheduled for October 29 at Pegasus Park in Dallas, the theme of the INVEST Digital Health conference will be consumers in healthcare from d2c diagnostics to GLP-1 drugs and wearables. Register today!
MedCity News' new event for healthcare investors and corporate business development leads — Bullseye — hit the mark when it comes to provocative and thoughtful commentary. Here's what was said in panels throughout the day.
Drug spending continues to grow, but that doesn’t mean that everyone is getting the medicines that they need. A panel at MedCity News’ Bullseye event discussed the evolution of the prescription drug marketplace.
Healthcare does not lack the data needed to better understand oncology costs. What it does lack is a consistent way to connect clinical progression with financial impact in a time frame that aligns with strategic planning.
Without knowledge of the exact amount providers billed and middlemen charged in fees, OPM can’t fix payment discrepancies.
When workers feel stuck in place, with limited opportunities to advance or deepen their skills, disengagement tends to follow. In allied health roles, where burnout is already high and many touch the patient experience, it is a risk healthcare employers cannot afford to ignore.
Alternative health plan designs represent much more than a passing trend. They are actively testing long-standing assumptions about how benefits should be structured, delivered, and experienced.
The challenge isn’t just access to fertility benefits, it’s how those benefits are structured and delivered. Here are three emerging themes that can help employers better align cost, quality and experience.
The rise of metabolic gene therapies represents a critical juncture for benefits management. These treatments offer genuine hope for patients with serious conditions, but they also pose significant financial challenges.
Financial wellness cannot depend solely on education. It requires addressing the real obstacles that prevent employees from achieving financial stability. Medical debt is one of those obstacles.
Selective contracting, use of AI, networking volatility and interest in value-based care are some of the larger trends affecting the dental and vision benefits market.
This isn't a supply problem. It's a distribution problem. The physicians exist. The system just isn't getting them where they need to be.